| Vienna % | Pécs % | Florence % | Niš % | Ljubljana % | Zurich % | All | % | |||||||
| Patients, n | 99 | 145 | 74 | 69 | 113 | 125 | 625 | |||||||
| Sm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| U1-snRNP | 2 | 2.0 | 9 | 6.2 | 1 | 1.4 | 11 | 15.9 | 11 | 9.6 | 4 | 3.2 | 38 | 6.1 |
| Ro | 11 | 11.0 | 9 | 6.2 | 3 | 4.1 | 6 | 8.7 | 15 | 13.2 | 8 | 6.4 | 52 | 8.3 |
| La | 2 | 2.0 | 3 | 2.1 | 1 | 1.4 | 1 | 1.4 | 3 | 2.6 | 1 | 0.8 | 11 | 1.8 |
| Scl70 | 30 | 30.0 | 31 | 21.4 | 7 | 9.5 | 11 | 15.9 | 25 | 21.9 | 26 | 20.8 | 130 | 20.8 |
| Ku | 1 | 1.00 | 3 | 2.07 | 0 | 2 | 2.90 | 8 | 7.02 | 0 | 14 | 2.2 | ||
| Jo-1 | 1 | 1.0 | 0 | 0 | 1 | 1.4 | 1 | 0.9 | 0 | 0.0 | 3 | 0.5 | ||
| PM/Scl | 5 | 5.0 | 2 | 1.4 | 0 | 0 | 7 | 6.1 | 4 | 3.2 | 18 | 2.9 | ||
| SL | 3 | 3.0 | 4 | 2.8 | 1 | 1.4 | 1 | 1.4 | 2 | 1.8 | 0 | 0.0 | 11 | 1.8 |
| PCNA | 0 | 0 | 0 | 0 | 1 | 0.9 | 0 | 1 | 0.2 | |||||
| UDA | 12 | 12.0 | 9 | 6.2 | 5 | 6.8 | 5 | 7.2 | 16 | 14.8 | 15 | 12.0 | 62 | 9.9 |
| ENA/CIE negative* | 52 | 52.0 | 91 | 62.8 | 59 | 79.7 | 42 | 60.9 | 41 | 36.0 | 81 | 64.8 | 366 | 58.6 |
*Anti-ENA (antibodies negative by CIE).
CIE, counterimmunoelectrophoresis; Jo-1, histidyl-t-RNA synthetase; La, SS-B; PCNA, proliferating cell nuclear antigen; PM/Scl. polymyositis/scleroderma; Ro, SS-A; Scl70, DNA topoisomerase 1; SL, sicca/lupus; Sm, Smith; UDA, undifferentiated autoantibodies.